October 18, 2024
2 min watch
Save
VIDEO: Aurion outlines next steps for corneal endothelial cell therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Greg Kunst of Aurion Biotech provides an update on the company’s cell therapy for corneal endothelial disease.
Aurion, which received breakthrough therapy and regenerative medicine advanced therapy designations in June, plans to release phase 2 data within the coming months. Kunst also discussed the recent reimbursement approval for the therapy in Japan and how this highlights the therapy’s promise.
“We don’t tend to see phase 2 biotech companies having commercial experience in major markets,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kunst reports being CEO of Aurion Biotech.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.